• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?

作者信息

Tanaka Yoshiya

机构信息

The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

出版信息

Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i1-i3. doi: 10.1093/rheumatology/key280.

DOI:10.1093/rheumatology/key280
PMID:30806705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6390877/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de8c/6390877/00c362025e8f/key280f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de8c/6390877/00c362025e8f/key280f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de8c/6390877/00c362025e8f/key280f1.jpg

相似文献

1
The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?JAK抑制剂：它们会给风湿性疾病的治疗带来范式转变吗？
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i1-i3. doi: 10.1093/rheumatology/key280.
2
[Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].[类风湿关节炎的诊断与治疗：迈向最佳实践。JAK抑制剂的最佳应用。]
Clin Calcium. 2018;28(5):678-685.
3
[JAK inhibitors in the management of rheumatoid arthritis].[JAK抑制剂在类风湿关节炎治疗中的应用]
Rev Med Suisse. 2019 Mar 6;15(641):528-532.
4
Expanded table: some biologic agents and JAK inhibitors for RA.扩展表格：一些用于类风湿关节炎的生物制剂和JAK抑制剂。
Med Lett Drugs Ther. 2018 Jul 30;60(1552):e130-e134.
5
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?JAK 抑制剂在风湿病学中的应用：对儿科综合征的影响？
Curr Rheumatol Rep. 2018 Nov 8;20(12):83. doi: 10.1007/s11926-018-0792-7.
6
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.西班牙一个由1037名接受生物制剂和JAK抑制剂治疗的风湿病患者组成的队列中重症新型冠状病毒肺炎的发病率。
Ann Rheum Dis. 2022 Jul;81(7):e131. doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25.
7
What is the true incidence of COVID-19 in patients with rheumatic diseases?风湿性疾病患者中新型冠状病毒肺炎的真实发病率是多少？
Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.
8
Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?类风湿关节炎中JAK抑制剂的效益风险比情况如何？
Joint Bone Spine. 2022 Nov;89(6):105454. doi: 10.1016/j.jbspin.2022.105454. Epub 2022 Aug 12.
9
The cardiovascular risk of JAK inhibitors in treating rheumatic diseases.JAK抑制剂在治疗风湿性疾病中的心血管风险。
Int J Rheum Dis. 2024 Aug;27(8):e15308. doi: 10.1111/1756-185X.15308.
10
[Small molecules treatment in rheumatoid arthritis].[小分子药物治疗类风湿关节炎]
Rev Med Suisse. 2020 Mar 11;16(685):477-480.

引用本文的文献

1
Current progress and future perspective of super-enhancers: a viable and effective bridge between the transcriptional apparatus and disease.超级增强子的当前进展与未来展望：转录装置与疾病之间可行且有效的桥梁
Front Genet. 2025 Jul 2;16:1611905. doi: 10.3389/fgene.2025.1611905. eCollection 2025.
2
A case report of systemic lupus erythematosus complicating interstitial lung disease and thickened pericardium treated with tofacitinib.托法替布治疗系统性红斑狼疮合并间质性肺病和心包增厚 1 例报告。
Medicine (Baltimore). 2024 Jul 26;103(30):e39129. doi: 10.1097/MD.0000000000039129.
3
Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics.

本文引用的文献

1
Janus kinases to jakinibs: from basic insights to clinical practice.Janus 激酶到 jakinibs：从基础研究到临床实践。
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i4-i16. doi: 10.1093/rheumatology/key432.
2
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.JAK 抑制剂。类风湿关节炎之外，免疫介导性疾病领域的新玩家。
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43-i54. doi: 10.1093/rheumatology/key276.
3
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
在对 Janus 激酶抑制剂和后续生物制剂治疗反应不佳的难治性类风湿关节炎患者中，使用第二种 Janus 激酶抑制剂时的药物生存和疾病活动变化。
Adv Rheumatol. 2024 Apr 15;64(1):26. doi: 10.1186/s42358-024-00368-w.
4
Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?为什么我们需要 JAK 抑制剂治疗系统性红斑狼疮？
Int J Mol Sci. 2022 Oct 4;23(19):11788. doi: 10.3390/ijms231911788.
5
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.风湿免疫领域的 Janus 激酶靶向治疗：一种基于机制的方法。
Nat Rev Rheumatol. 2022 Mar;18(3):133-145. doi: 10.1038/s41584-021-00726-8. Epub 2022 Jan 5.
6
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.类风湿关节炎治疗的最新进展：生物制剂和小分子药物的发展概述，以及未满足的需求。
Rheumatology (Oxford). 2021 Dec 24;60(Suppl 6):vi12-vi20. doi: 10.1093/rheumatology/keab609.
7
Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan.台湾类风湿关节炎患者生物改善病情抗风湿药和托法替布的转换及停药模式
Front Pharmacol. 2021 Jul 21;12:628548. doi: 10.3389/fphar.2021.628548. eCollection 2021.
8
The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?比较 COVID-19、H1N1 流感、CRS 和 MAS 的细胞因子风暴。一种治疗方法能适用于所有情况吗？
Cytokine. 2021 Aug;144:155593. doi: 10.1016/j.cyto.2021.155593. Epub 2021 May 26.
9
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.在真实临床实践中，托法替布与巴瑞替尼治疗类风湿关节炎患者的疗效和安全性：基于倾向评分逆概率治疗加权的分析。
Ann Rheum Dis. 2021 Sep;80(9):1130-1136. doi: 10.1136/annrheumdis-2020-219699. Epub 2021 Apr 7.
10
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview.类风湿关节炎患者骨质疏松和关节损伤的管理：概述
J Clin Med. 2021 Mar 17;10(6):1241. doi: 10.3390/jcm10061241.
越来越多的证据表明 JAK 抑制剂在类风湿关节炎患者中的安全性。
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i34-i42. doi: 10.1093/rheumatology/key287.
4
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.JAK 抑制剂在类风湿关节炎中的临床疗效。
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i17-i26. doi: 10.1093/rheumatology/key225.
5
Clinical efficacy of new JAK inhibitors under development. Just more of the same?正在研发的新型 JAK 抑制剂的临床疗效。只是大同小异？
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i27-i33. doi: 10.1093/rheumatology/key256.
6
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.巴利替尼与安慰剂或阿达木单抗治疗类风湿关节炎的疗效比较。
N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.
7
Rheumatoid arthritis.类风湿关节炎
Lancet. 2016 Oct 22;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3.
8
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.类风湿关节炎JAK抑制剂的最新进展与展望：从实验台到临床应用
J Biochem. 2015 Sep;158(3):173-9. doi: 10.1093/jb/mvv069. Epub 2015 Jul 7.
9
Janus kinase inhibitors in autoimmune diseases.自身免疫性疾病中的 Janus 激酶抑制剂。
Ann Rheum Dis. 2013 Apr;72 Suppl 2(0 2):ii111-5. doi: 10.1136/annrheumdis-2012-202576.
10
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.托法替尼或阿达木单抗与安慰剂治疗类风湿关节炎的比较。
N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072.